Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism

Thomas A. Buchanan, Hemant Thawani, Wagdy Kades, J. Gregory Modrall, Fred A. Weaver, Constance Laurel, Roberta Poppiti, Anny Xiang, Willa Hsueh

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (∼115 μU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (∼5,000 μU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (∼13 μU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.

Original languageEnglish (US)
Pages (from-to)720-726
Number of pages7
JournalJournal of Clinical Investigation
Volume92
Issue number2
StatePublished - Aug 1993

Fingerprint

Hyperinsulinism
Angiotensin II
Hemodynamics
Glucose
Insulin
Leg
Insulin Resistance
Kidney
Glucose Clamp Technique
Renin-Angiotensin System
Skeletal Muscle

Keywords

  • Angiotensin II
  • Blood flow
  • Hemodynamics
  • Hypertension
  • Insulin sensitivity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Buchanan, T. A., Thawani, H., Kades, W., Modrall, J. G., Weaver, F. A., Laurel, C., ... Hsueh, W. (1993). Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. Journal of Clinical Investigation, 92(2), 720-726.

Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. / Buchanan, Thomas A.; Thawani, Hemant; Kades, Wagdy; Modrall, J. Gregory; Weaver, Fred A.; Laurel, Constance; Poppiti, Roberta; Xiang, Anny; Hsueh, Willa.

In: Journal of Clinical Investigation, Vol. 92, No. 2, 08.1993, p. 720-726.

Research output: Contribution to journalArticle

Buchanan, TA, Thawani, H, Kades, W, Modrall, JG, Weaver, FA, Laurel, C, Poppiti, R, Xiang, A & Hsueh, W 1993, 'Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism', Journal of Clinical Investigation, vol. 92, no. 2, pp. 720-726.
Buchanan, Thomas A. ; Thawani, Hemant ; Kades, Wagdy ; Modrall, J. Gregory ; Weaver, Fred A. ; Laurel, Constance ; Poppiti, Roberta ; Xiang, Anny ; Hsueh, Willa. / Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. In: Journal of Clinical Investigation. 1993 ; Vol. 92, No. 2. pp. 720-726.
@article{b62bbb0cc023425c932316b4837d03f9,
title = "Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism",
abstract = "To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (∼115 μU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (∼5,000 μU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (∼13 μU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.",
keywords = "Angiotensin II, Blood flow, Hemodynamics, Hypertension, Insulin sensitivity",
author = "Buchanan, {Thomas A.} and Hemant Thawani and Wagdy Kades and Modrall, {J. Gregory} and Weaver, {Fred A.} and Constance Laurel and Roberta Poppiti and Anny Xiang and Willa Hsueh",
year = "1993",
month = "8",
language = "English (US)",
volume = "92",
pages = "720--726",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism

AU - Buchanan, Thomas A.

AU - Thawani, Hemant

AU - Kades, Wagdy

AU - Modrall, J. Gregory

AU - Weaver, Fred A.

AU - Laurel, Constance

AU - Poppiti, Roberta

AU - Xiang, Anny

AU - Hsueh, Willa

PY - 1993/8

Y1 - 1993/8

N2 - To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (∼115 μU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (∼5,000 μU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (∼13 μU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.

AB - To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (∼115 μU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (∼5,000 μU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (∼13 μU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.

KW - Angiotensin II

KW - Blood flow

KW - Hemodynamics

KW - Hypertension

KW - Insulin sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0027282791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027282791&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 720

EP - 726

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -